BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT® Technology
News Oct 25, 2007
BioWa, Inc. has announced that it has entered into a second agreement with MedImmune to provide additional access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using ADCC enhanced antibodies.
"We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca's plans to establish a major international presence in the research and development of biological therapeutics," said Dr. Masamichi Koike, President and CEO of BioWa. "With MedImmune's superior expertise in antibody-based drug development, this collaboration complements BioWa's mission to bring about the benefit of POTELLIGENT® Technology to patients as quickly as possible."
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018